Influenza News and Research

Latest Influenza News and Research

Swine flu shots linked to narcolepsy: Investigation continues

The vaccine used against swine flu has been linked to a disorder called narcolepsy among those aged four to 19. Narcolepsy involves people falling asleep without warning or sleeping excessively in the daytime. A preliminary study also “observed [an] increase in incidence of narcolepsy” among those given the vaccine.

2 Feb 2011

Positive interim results from H5N1 Avian Influenza VLP vaccine Phase II human clinical trial

Medicago, a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles, today reported positive interim results from a Phase II human clinical trial with its H5N1 Avian Influenza VLP vaccine candidate.

1 Feb 2011

Positive interim results from Medicago's Phase II clinical trial of H5N1 Avian Influenza VLP vaccine

Medicago Inc. a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today reported positive interim results from a Phase II human clinical trial with its H5N1 Avian Influenza VLP vaccine candidate ("H5N1 vaccine"). The vaccine was found to be safe, well tolerated and also induced a solid immune response.

1 Feb 2011

HighRes Biosolutions to build High-Throughput Laboratory Network for LANL-UCLA

A compact, self-contained, automated system for surveillance and screening of potential pandemic strains of influenza and other deadly infectious diseases is a step closer to reality, thanks to an agreement between Los Alamos National Laboratory, the University of California Los Angeles School of Public Health, and HighRes Biosolutions of Boston, Massachussets.

1 Feb 2011

News briefs from February issue of journal Chest

New research shows that vitamin D deficiency is prevalent among patients with interstitial lung disease (ILD), with the largest prevalence seen in patients with concurrent connective tissue disease (CTD).

1 Feb 2011

New study: Swine flu transmission is most intensive between children of same class

Boys predominantly pass on flu to other boys and girls to girls, according to a new study of how swine flu spread in a primary school during the 2009 pandemic, published today in the journal Proceedings of the National Academy of Sciences. The results also suggest that flu transmission is most intensive between children of the same class, but that sitting next to an infected person does not significantly increase a child's risk of catching flu.

1 Feb 2011

Inovio announces regulatory approval for Phase 2 trial to treat leukemia using new vaccine delivery device

Inovio Pharmaceuticals, a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today the regulatory approval of a Phase 2 clinical trial to treat leukemia utilizing Inovio's new ELGEN 1000 automated vaccine delivery device.

31 Jan 2011

Research Project's efficient solution for early cancer detection receives Leonardo da Vinci Prize

International philanthropists are challenging the world to provide a Cancer Research Project offering the most efficient solution in Particle Physics for early cancer detection with the highest potential to reduce premature cancer death.

29 Jan 2011

European Commission grants approval for Johnson & Johnson's proposed acquisition of Crucell

Johnson & Johnson and Crucell today announced that the European Commission has granted approval for Johnson & Johnson's proposed acquisition of Crucell.

29 Jan 2011

Research roundup: Barriers to trauma care, immunizations; Small business tax credit; Medicare coverage of preventive care

Possible Geographical Barriers To Trauma Center Access For Vulnerable Patients In The United States - This study analyzes disparities in geographic access to trauma centers in 2005, drawing from data from the 2005 American Hospital Association annual survey.

29 Jan 2011

Preclinical data on Inovio’s intradermal electroporation delivery devices presented at Phacilitate Vaccine Forum

Inovio Pharmaceuticals, Inc., a leader in the development of novel therapeutic and preventive vaccines against cancers and infectious diseases, announced today the presentation of recent preclinical data using its next generation of minimally invasive intradermal (skin) electroporation delivery devices at the Phacilitate Vaccine Forum 2011 in Washington, DC.

28 Jan 2011

Inovio to use proceeds from $24.3M offering for development of DNA vaccine against cervical dysplasias

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today the closing of the sale to a single institutional investor of 21,130,400 shares of its common stock and warrants to purchase up to 10,565,200 additional shares of its common stock.

28 Jan 2011

USPTO issues Notice of Allowances to Lakewood's three patent applications for treatment of HUS

Lakewood-Amedex, a leading developer of novel anti-infective pharmaceuticals, announced today that the United States Patent and Trademark Office has issued Notice of Allowances on three patent applications relating to the use of novel monoclonal antibodies for the treatment of hemolytic uremic syndrome caused by shiga toxin II secreting E.coli O157: H7 strain.

28 Jan 2011

HIV causes specific subset of CD4+ T-cells to age rapidly: Study

In the early years of the AIDS epidemic, being infected with the virus that causes the disease was considered a virtual death sentence. But with the development of antiretroviral therapy, many with HIV are now living much longer. In fact, it is estimated that by 2015, about half of all HIV-positive individuals will be older than 50.

28 Jan 2011

Lancet series examines health issues facing populations in Southeast Asia

"Southeast Asia's 600 million people are facing a raft of new health challenges as the disaster-prone region undergoes some of the world's fastest social change," according to a series of papers and commentary pieces, published Tuesday in the Lancet, Agence France-Presse reports (O'Brien, 1/25).

27 Jan 2011

Inviragen completes memorandum of understanding with Duke-NUS

Inviragen, and the Duke-National University of Singapore Graduate Medical School announced today that they have completed a memorandum of understanding to establish a partnership between the two organizations.

27 Jan 2011

Researchers find White-Hispanic disparities in receiving immunization against flu, pneumonia

Seniors of Hispanic descent are far less likely to become immunized against the flu or pneumonia compared to similar White seniors, according to a new RAND Corporation study.

25 Jan 2011

Eliminating sugary drinks from diet can reduce tooth decay in American Indian children

A study conducted in four American Indian communities in the Pacific Northwest presents an effective strategy to convince mothers to switch young children from drinking sweetened soda to water and shows that eliminating these sugary drinks from the diets of the youngest members of the tribe significantly decreased tooth decay.

24 Jan 2011

CRI, Oncovir sign new investment agreement to produce immunological stimulant

Cancer Research Institute, a U.S. nonprofit organization founded in 1953 to advance the science of tumor immunology and foster the discovery and development of new cancer immunotherapies, announced today that its Cancer Vaccine Acceleration Fund, a joint initiative with the Ludwig Institute for Cancer Research, has completed a new investment agreement with Oncovir, a biotechnology company based in Washington, D.C., to enable the production of the immunological stimulant Hiltonol- (Poly-ICLC).

24 Jan 2011

CVAF completes new investment agreement with Oncovir for production of Hiltonol

Cancer Research Institute, Inc. (CRI), a U.S. nonprofit organization founded in 1953 to advance the science of tumor immunology and foster the discovery and development of new cancer immunotherapies, announced today that its Cancer Vaccine Acceleration Fund (CVAF), a joint initiative with the Ludwig Institute for Cancer Research (LICR), has completed a new investment agreement with Oncovir, Inc., a biotechnology company based in Washington, D.C., to enable the production of the immunological stimulant Hiltonol® (Poly-ICLC).

21 Jan 2011

Influenza News and Research

Latest Influenza News and Research

Swine flu shots linked to narcolepsy: Investigation continues

Positive interim results from H5N1 Avian Influenza VLP vaccine Phase II human clinical trial

Positive interim results from Medicago's Phase II clinical trial of H5N1 Avian Influenza VLP vaccine

HighRes Biosolutions to build High-Throughput Laboratory Network for LANL-UCLA

News briefs from February issue of journal Chest

New study: Swine flu transmission is most intensive between children of same class

Inovio announces regulatory approval for Phase 2 trial to treat leukemia using new vaccine delivery device

Research Project's efficient solution for early cancer detection receives Leonardo da Vinci Prize

European Commission grants approval for Johnson & Johnson's proposed acquisition of Crucell

Research roundup: Barriers to trauma care, immunizations; Small business tax credit; Medicare coverage of preventive care

Preclinical data on Inovio’s intradermal electroporation delivery devices presented at Phacilitate Vaccine Forum

Inovio to use proceeds from $24.3M offering for development of DNA vaccine against cervical dysplasias

USPTO issues Notice of Allowances to Lakewood's three patent applications for treatment of HUS

HIV causes specific subset of CD4+ T-cells to age rapidly: Study

Lancet series examines health issues facing populations in Southeast Asia

Inviragen completes memorandum of understanding with Duke-NUS

Researchers find White-Hispanic disparities in receiving immunization against flu, pneumonia

Eliminating sugary drinks from diet can reduce tooth decay in American Indian children

CRI, Oncovir sign new investment agreement to produce immunological stimulant

CVAF completes new investment agreement with Oncovir for production of Hiltonol

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Influenza News and Research

Latest Influenza News and Research

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Newsletters you may be interested in